Literature DB >> 29628987

Benign Intraductal Papilloma without Atypia on Core Needle Biopsy Has a Low Rate of Upgrading to Malignancy after Excision.

Song-Hee Han1,2, Milim Kim1, Yul Ri Chung1, Bo La Yun3, Mijung Jang3, Sun Mi Kim3, Eunyoung Kang4, Eun-Kyu Kim4, So Yeon Park1.   

Abstract

PURPOSE: The management of benign intraductal papilloma (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial. This study was performed to evaluate the rate of upgrading to malignancy or high-risk lesions after excision and to identify factors associated with upgrading using a large series of benign IDP cases without atypia.
METHODS: We included patients who were diagnosed as having benign IDP without atypia on CNB and underwent surgical or vacuum-assisted excision between 2010 and 2015. We analyzed the clinical, radiologic, and histopathologic features of IDPs that were upgraded to malignancy or high-risk lesions after excision.
RESULTS: A total of 511 benign IDPs without atypia diagnosed via CNB were identified, of which 398 cases were treated with excision. After reviewing these cases, four cases of high-risk lesions in adjacent tissue on CNB, two cases which were revealed as papilloma with atypia, and nine cases of malignancy in the same breast were excluded. In the remaining 383 cases, the rate of upgrading to malignancy and high-risk lesions after excision was 0.8% and 4.4%, respectively. The presence of concurrent contralateral breast cancer, the presence of symptoms, and multifocality were factors significantly associated with upgrading to malignancy on subsequent excision. Surgical excision rather than vacuum-assisted excision was significantly associated with upgrading to high-risk lesions or malignancy.
CONCLUSION: The rate of upgrading to malignancy for benign IDP without atypia was very low, suggesting that close clinical and radiologic observation may be sufficient for patients with benign IDP without atypia on CNB under proper settings.

Entities:  

Keywords:  Breast neoplasms; Large-core needle biopsy; Observation; Papilloma

Year:  2018        PMID: 29628987      PMCID: PMC5880969          DOI: 10.4048/jbc.2018.21.1.80

Source DB:  PubMed          Journal:  J Breast Cancer        ISSN: 1738-6756            Impact factor:   3.588


INTRODUCTION

Intraductal papilloma (IDP) originates from both the large ducts of the subareolar region and the terminal duct lobular unit in the periphery, and it is histologically characterized by a fibrovascular core covered with epithelial and myoepithelial cells. It is a relatively common lesion found in breast biopsies. However, IDP often accompanies a variety of changes, including sclerosis, epithelial or myoepithelial hyperplasia, squamous or apocrine metaplasia, and even atypical proliferation [1]. A papilloma with atypia, which encompasses atypical ductal hyperplasia (ADH) or small foci of low-grade ductal carcinoma in situ (DCIS) within the papilloma, has an increased risk of developing malignancy and has been reported to show a high rate of upgrading on subsequent excision [2345]. Thus, surgical excision is usually recommended for IDP with atypia diagnosed by core needle biopsy (CNB) as standard management. On the contrary, no consensus has been met regarding the management of benign IDP without atypia diagnosed by CNB harboring no clinical symptoms. Some studies have shown that IDPs, even those without atypia, are significantly associated with higher-grade lesions [46], and surgical excision is recommended in all cases for accurate diagnosis. In contrast, other studies have shown low rates of upgrading for IDP without atypia, suggesting careful observation rather than surgical excision [7891011]. However, most of the previous studies were performed using small samples, and some studies included IDP with atypia or even malignancy in their analysis. In the present study, we restricted our analysis to a large cohort of benign IDPs without atypia, and we evaluated the upgrade rate to malignancy, including DCIS and invasive carcinoma. In addition, evaluation of the presence of proliferative lesions with atypia, such as ADH, atypical lobular hyperplasia, and lobular carcinoma in situ, which are associated with a high risk for developing breast cancer, is also important in assessing breast cancer risk and determining patient management. Thus, we evaluated the upgrade rate to these high-risk lesions as well. Furthermore, we analyzed the clinicopathologic features associated with upgrading on excision.

METHODS

Case selection

We performed a retrospective search of the pathology database to identify IDPs without atypia diagnosed via CNB between January 2010 and December 2015 at the Department of Pathology, Seoul National University Bundang Hospital, Korea. All CNBs were performed using a 14-gauge automated biopsy gun (STERICUT®; TSK Laboratory, Tochigi, Japan) under ultrasound guidance by radiologists specialized in breast imaging. We selected cases that were excised with lumpectomy, excisional biopsy, or vacuum-assisted excision (VAE) at our institution. When patients presented with symptoms such as bloody nipple discharge or a palpable mass or when IDP was located near the skin or nipple, surgical management was recommended. When the lesion was single with a size less than 3 cm and located far from the skin or nipple, patients had an option of surgery or VAE. VAE was performed using an 8- or 11-gauge vacuum-assisted biopsy needle (Mammotome®; Devicor Medical Products, Cincinnati, USA). Benign IDPs with benign proliferative lesions, such as usual ductal hyperplasia or adenosis, and those associated with sclerosis, radial scars, fibrocystic changes, and columnar cell changes, were included. IDPs coexisting with a malignant lesion, including invasive carcinoma and DCIS, or other highrisk lesions, such as ADH and lobular neoplasia (atypical lobular hyperplasia and lobular carcinoma in situ), in the same side of the breast were excluded. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (protocol number: B-1708-414-107) and informed consent was waived.

Evaluation of clinical and radiologic features

Clinical variables, such as the age at the time of diagnosis; gender; cause of detection; clinical symptoms, including nipple discharge, palpable mass, and local pain; and history of breast cancer, were recorded. Radiologic findings, including the location of the lesion, size of the lesion defined as the largest dimension recorded on imaging, Breast Imaging Reporting and Data System (BI-RADS) classification of the lesion, multifocality, and the number of tissue cores in CNB, were retrieved from the medical records. Multifocality was defined as two or more lesions separated by normal breast tissue in imaging that were eventually proven to be benign IDPs on pathologic examination. To analyze the radiologic-pathologic concordance, we reviewed all radiologic findings in each case and matched them with the pathologic diagnosis by the location of the CNB and the size of the lesion. Radiologic-pathologic discordance was considered to be present when the lesion was more than moderately suspicious for malignancy in radiologic findings, i.e., BI-RADS category 4b, 4c, or 5, but for which the histologic findings of IDP without atypia did not account for the imaging pattern.

Evaluation of excision specimens

We aszsessed accompanying lesions within the papilloma or in the adjacent breast tissue using excision specimens, and we classified them according to the World Health Organization classification of Tumours of the Breast, 4th edition. Upgrade to malignancy was defined as the presence of invasive carcinoma or DCIS in the excision specimen. The presence of atypical proliferative lesions such as ADH and lobular neoplasia, which are associated with a high risk of malignancy, was also assessed. Upgrade to high-risk lesions was defined as the presence of ADH or lobular neoplasia.

Statistical analysis

Statistical analysis was performed using SPSS version 21.0 software (IBM Corp., Armonk, USA). For patients with more than one IDP, analyses of the radiologic and pathologic features were based on each IDP. Chi-square tests or Fisher exact tests were used to compare the clinicopathologic variables between upgraded lesions and nonupgraded lesions. Statistical significance was defined as a p-value <0.05. All reported p-values were two-sided.

RESULTS

Clinical, radiologic, and pathologic characteristics of IDP on CNB

A total of 511 benign IDPs without atypia diagnosed by CNB were identified, of which 398 cases were treated with surgical excision or VAE at our institution. After reviewing the medical records, pathologic reports, and hematoxylin and eosin stained slides of the CNBs, four cases that had high-risk lesions in the adjacent tissue, two cases that were re-diagnosed as papilloma with atypia, and nine cases of concurrent breast cancer in the same breast were excluded. Finally, 383 cases of benign IDP without atypia were included in the analyses. The median age of the patients at the time of biopsy was 48 years (range, 23–82 years). In this cohort, the two major causes of initial detection were routine mammographic screening on medical checkup (n=224, 58.5%) and the presence of a symptom (n=108, 28.2%). All breast CNBs were performed under ultrasound guidance. The median number of core biopsy samples was 5 (range, 1–15). The other baseline characteristics of the patients are described in Table 1.
Table 1

Baseline characteristics (n=383)

CharacteristicNo. (%)
Age (yr)*48 (23–82)
Cause of detection
 Medical checkup224 (58.5)
 Presence of symptom108 (28.2)
  Nipple discharge67
  Palpable mass34
  Local pain7
 Radiologic abnormality detected during examination of other lesions51 (13.3)
Concurrent contralateral breast cancer
 Yes32 (8.4)
 No351 (91.6)
Side
 Right178 (46.5)
 Left205 (53.5)
Subareolar location
 Yes50 (13.1)
 No333 (86.9)
Radiologic size (cm)*0.8 (0.3–4.2)
BI-RADS classification
 C32 (0.5)
 C4a348 (90.9)
 C4b29 (7.6)
 C4c4 (1.0)
Radiologic identification of intraductal lesion
 Yes72 (18.8)
 No311 (81.2)
Multifocality
 No292 (76.2)
 Yes91 (23.8)
No. of cores in CNB*5 (1–15)
Method of procedure after CNB
 VAE226 (59.0)
 Surgical excision157 (41.0)

BI-RADS=Breast Imaging Reporting and Data System; CNB=core needle biopsy; VAE=vacuum-assisted excision.

*Median (range).

Characteristics of IDPs with a likelihood of upgrading to malignancy or high-risk lesions on excision

Among the 383 IDPs without atypia on CNB, 20 cases (5.2%) were upgraded to malignancy or high-risk lesions, including ADH and lobular neoplasia, on excision; 10 cases were upgraded to ADH, five to atypical lobular hyperplasia, two to lobular carcinoma in situ, and three to DCIS. The rate of upgrading to malignancy and high-risk lesions after excision was 0.8% (n=3) and 4.4% (n=17), respectively. We also evaluated the characteristics of the lesions upgraded to malignancy on excision. Interestingly, we found that the presence of a symptom (p=0.022), the presence of concurrent contralateral breast cancer (p=0.019), and multifocality of the lesions (p=0.013) were predictive factors for upgrading to malignancy (Table 2). In addition, cases upgraded to malignancy or high-risk lesions were associated with surgical excision after CNB (p<0.001). The presence of concurrent contralateral breast cancer tended to have an association with upgrading to malignancy or high-risk lesions (p=0.075) (Table 3).
Table 2

Characteristics of intraductal papillomas without atypia upgraded to malignancy on subsequent excision

CharacteristicNot upgraded to malignancy (n = 380)Upgraded to malignancy (n = 3)p-value
Age (yr)0.260
 < 50213 (56.1)3 (100)
 ≥ 50167 (43.9)0
Side0.099
 Right175 (46.1)3 (100)
 Left205 (53.9)0
Subareolar area0.344
 Yes49 (12.9)1 (33.3)
 No331 (87.1)2 (66.7)
Presence of symptom0.022
 Yes105 (27.6)3 (100)
 No275 (72.4)0
Concurrent contralateral breast cancer0.019
 Yes30 (7.9)2 (66.7)
 No350 (92.1)1 (33.3)
Radiologic size (cm)0.271
 < 0.8158 (41.6)0
 ≥ 0.8222 (58.4)3 (100)
BI-RADS classification0.409
 C32 (0.5)0
 C4a346 (91.1)2 (66.7)
 C4b28 (7.4)1 (33.3)
 C4c4 (1.0)0
Radiologic identification of intraductal lesion1.000
 Yes72 (18.9)0
 No308 (81.1)3 (100)
Multifocality0.013
 No292 (76.8)0
 Yes88 (23.2)3 (100)
No. of cores in CNB*0.569
 <5151 (40.5)2 (66.7)
 ≥5222 (59.5)1 (33.3)
Method of procedure after CNB0.068
 Surgical excision154 (40.5)3 (100)
 VAE226 (59.5)0

p-values were calculated by Fisher exact test.

BI-RADS=Breast Imaging Reporting and Data System; CNB=core needle biopsy; VAE=vacuum-assisted excision.

*Information was available for 376 lesions.

Table 3

Characteristics of intraductal papillomas without atypia upgraded to malignancy or other high-risk lesions on subsequent excision

CharacteristicNot upgraded to malignancy or high risk lesions (n=363)Upgraded to malignancy or high risk lesions (n=20)p-value
Age (yr)0.739
 < 50204 (56.2)12 (60.0)
 ≥ 50159 (43.8)8 (40.0)
Location0.432
 Right167 (46.0)11 (55.0)
 Left196 (54.0)9 (45.0)
Subareolar area1.000
 Yes48 (13.2)2 (10.0)
 No315 (86.8)18 (90.0)
Presence of symptom0.854
 Yes102 (28.1)6 (30.0)
 No261 (71.9)14 (70.0)
Concurrent contralateral breast cancer0.075
 Yes28 (7.7)4 (20.0)
 No335 (92.3)16 (80.0)
Radiologic size (cm)0.560
 < 0.8151 (43.6)7 (35.0)
 ≥ 0.8212 (58.4)13 (65.0)
BI-RADS classification0.319
 C32 (0.6)0
 C4a331 (91.2)17 (85.0)
 C4b27 (7.4)2 (10.0)
 C4c3 (0.8)1 (5.0)
Radiologic identification of intraductal lesions0.142
 Yes71 (19.6)1 (5.0)
 No292 (80.4)19 (95.0)
Multifocality0.278
 No279 (76.9)13 (65.0)
 Yes84 (23.1)7 (35.0)
No. of cores in CNB*0.687
 <5144 (40.4)9 (45.0)
 ≥5212 (59.6)11 (55.0)
Method of procedure after CNB< 0.001
 Surgical excision139 (38.3)18 (90.0)
 VAE224 (61.7)2 (10.0)

p-values were calculated by the chi-square or Fisher exact test.

BI-RADS=Breast Imaging Reporting and Data System; CNB=core needle biopsy; VAE=vacuum-assisted excision.

*Information was available for 376 lesions.

Characteristics of the cases upgraded to malignancy on excision

The clinical and pathologic characteristics of the cases that were upgraded to malignant lesions are summarized in Table 4. All of these cases were upgraded to DCIS, which was found around the papilloma (Figure 1). The extent of the DCIS was 0.5 cm, 2.5 cm, and 2.5 cm in each case. Of these three cases, two were from the same patient. All of the cases had clinical symptoms: one manifested as nipple discharge and the others as a palpable mass. Radiologic size of the lesions was 0.8 cm or greater and showed multifocality. Two cases had concurrent contralateral breast cancer.
Table 4

Summary of the characteristics of the lesions upgraded to malignancy on excision

CharacteristicCase 1Case 2Case 3
Age (yr)344040
SymptomsNipple dischargePalpable massPalpable mass
SideRightRightRight
Radiologic features
 Size (cm)1.92.90.8
 BI-RADS categoryC4aC4bC4a
 MultifocalityYesYesYes
No. of cores446
Excisional specimen
 Method of excisionSurgical excisionSurgical excisionSurgical excision
 DiagnosisDCISDCISDCIS
 Extent of malignancy (cm)0.52.52.5
 Location of malignancyAround papillomaAround papillomaAround papilloma
Concurrent contralateral breast cancerNoYesYes
 Pathologic diagnosisNAMCMC
Incidental upgradeNoNoNo

Case 2 and 3 were of the same patient.

BI-RADS=Breast Imaging Reporting and Data System; DCIS=ductal carcinoma in situ; NA=not applicable; MC=mucinous carcinoma.

Figure 1

A representative case upgraded to ductal carcinoma in situ on excision. (A) Core needle biopsy shows typical benign intraductal papilloma without atypia (H&E stain, ×100). (B) Excision specimen reveals small foci of ductal carcinoma in situ with intermediate nuclear grade and a cribriform architectural pattern (H&E stain, ×200). (C) Residual papilloma in the excision specimen does not show any atypical proliferative change. Postbiopsy changes are seen in the lower portion of the papilloma (H&E stain, ×100).

DISCUSSION

Advances in screening and imaging techniques for breast cancer have resulted in an increased number of suspicious lesions, which in turn, have led to an increased number of breast biopsies. The incidence of papillary lesions, including IDPs, has increased steadily over the past decade [12]. However, management of benign IDPs without atypia diagnosed by CNB remains controversial with some suggesting follow-up imaging and others excision. Moreover, in previous studies, the reported upgrading rates of benign IDP following excision vary widely [47891011131415]. This difference may have resulted from the study design, definition of upgrade lesions, and methodological details. Thus, we carefully selected our cohort to include only benign IDP cases diagnosed by CNB that had no malignant or high-risk lesions in the same breast. In this study, we showed that the rate of upgrading to malignancy was 0.8% at our institution. In addition, we found that the presence of a symptom, concurrent contralateral breast cancer, and multifocality were significant factors predictive of upgrading to malignancy. We also showed that upgrading to malignancy or high-risk lesions was associated with surgical excision rather than VAE. However, this may be caused by selection bias since patients with symptoms or multiple lesions were generally treated with surgical excision. Several studies have attempted to identify factors that are associated with upgrading of benign IDP on subsequent excision [7916171819202122]. It was reported that old age at diagnosis was associated with upgrading to malignancy in benign IDPs [1622]. Regarding the size of the lesion, IDPs upgraded to malignancy have been reported to be larger [71722]. Previously, we also showed that large-sized IDP was a significant predictor of an upgrade by analyzing solitary IDPs diagnosed at different time points at our institution, excluding patients with breast cancer [9]. Although the size of the IDP was not a significant factor associated with upgrading to malignancy in the present study, all upgraded cases were above the median in size. Besides the size of the lesion, Kil et al. [18] have suggested that peripherally located IDPs require additional surgical excision. Holley et al. [19] reported that a reduced amount of tissue collected at biopsy (three cores vs. five cores; 14-gauge vs. 9-gauge needle) was associated with an upgraded lesion. Additionally, previous studies have reported varying results regarding the impact of the BI-RADS category on upgrade rates in benign IDP [2021]. Contrary to the previous studies, patient age, size, and location of the lesion, number of tissue cores, and BI-RADS score were not proven to be significant factors in our study. The most noticeable predictor of upgrading to malignancy was the presence of concurrent contralateral breast cancer, a finding that has never been reported in previous studies. While only 7.9% (30/380) of the nonupgraded cases had concurrent contralateral breast cancer, 66.7% (2/3) of upgraded cases had concurrent contralateral breast cancer. This association may be explained by the fact that the risk of developing new breast cancer is increased in patients with a history of breast cancer [23]. We also found that multifocality of the lesion was a significant predictor for upgrading to malignancy, similar to previous studies that showed that multiple papillomas were more likely to be associated with breast cancer than solitary papillomas [2425]. The mismatch between radiologic findings and pathologic diagnosis is an important issue that requires further evaluation. Some studies have documented that the discordance between radiographic and histologic findings was an important factor that should be evaluated by surgical excision. Thus, inclusion or exclusion of pathologic-radiologic discordant cases may be an important factor leading to variability in upgrade rates. After analyzing 234 benign IDPs, Rizzo et al. [26] reported the rate of upgrading to DCIS and invasive carcinoma as 8.9% and to ADH as 17.9%. Shin et al. [27] showed that an upgrade rate to DCIS and invasive carcinoma was 14% of 86 benign IDPs diagnosed by CNB. Mercado et al. [28] reported that 17% of 36 IDPs were upgraded to ADH. Other studies have reported similar high upgrade rates though these results may raise doubts about the definition of an upgrade [12930]. Collectively, these studies included pathologic-radiologic discordant cases in their analyses or failed to document pathologic-radiologic concordance [12627282930], leading to falsely high upgrade rates. Shin et al. [27] reported that the upgrade rate to malignancy was higher in imaging-pathologic discordant lesions than in concordant lesions. However, recent studies reported that the upgrade rate for benign IDP is low when the pathologic-radiologic discordant cases are excluded [1011]. Although physical findings such as a palpable mass and nipple discharge may not predict the risk of upgrading, lesions with such manifestations require careful evaluation and close observation and eventually need excision even if the pathologic diagnosis on CNB was benign. Nakhlis et al. [10] showed that the actual rate of upgrading in their study was 0% when they excluded both of the two patients from their cohort who presented with a clinically suspicious palpable mass. Other studies shared the same perspective, excluding symptomatic patients from their analyses of upgrading of benign IDP [819]. We agree that any patient with symptoms such as a palpable mass or nipple discharge should be treated by excision. Thus, of the 383 benign IDP diagnosed by CNB in our study, none of the cases were truly upgraded lesions when we excluded all three cases with clinical symptoms for which surgical treatment is indicated. Of the 17 cases upgraded to high-risk lesions, two cases had pathologic-radiologic discordance, and three cases had clinical symptoms. Therefore, the true upgrade rate to high-risk lesions was 3.1%. Given our results, close clinical and radiologic observation appear to be adequate for patients with benign IDP on CNB under proper clinical settings. Although IDP has a relatively simple histologic definition, it encompasses a wide variety of lesions. Papillary lesions are often diagnostically challenging for pathologists. IDP may have a complex glandular architecture and epithelial hyperplasia; histologic distinctions between luminal epithelial and myoepithelial cells or benign hyperplasia and atypical hyperplasia can be subtle, leading to misinterpretations on CNB. Thus, accurate interpretation by an experienced pathologist and an adequate amount of an accurately-targeted specimen are essential for correct diagnosis. In our institution, all breast CNBs were diagnosed by an experienced breast pathologist (S.Y.P.), which can affect diagnostic accuracy. It was reported that one of the reasons for such diagnostic difficulties might be the limited amounts and fragmentation of the samples [16]. Renshaw et al. [3] pointed out that the incidence of upgrading after excision was associated with the adequacy of sampling in biopsy specimens. Several studies have shown different upgrading rates of benign IDP to malignancy depending on the needle gauge used during biopsy [1819]. In the current study, the number of tissue cores was sufficient with a median value of 5.0, which appears to have contributed to the low rate of upgrades. In conclusion, the most significant finding of our study is that the rate of upgrading to malignancy of benign IDP without atypia diagnosed by CNB is very low. Moreover, when we excluded cases with suspicious clinical symptoms, the true rate of under-diagnosis in our cohort was 0%. For this reason, caution should be exercised in recommending surgical management for all benign IDPs. Our study suggests that patients with benign IDPs diagnosed by CNB who have solitary lesions without clinically suspicious symptoms and, in particular, no concurrent contralateral breast cancer may be candidates for close observation rather than prompt excision. However, due to the small number of cases upgraded to malignancy in this study, further large-scale studies are warranted to support this suggestion.
  30 in total

1.  Papilloma on core biopsy: excision vs. observation.

Authors:  Faina Nakhlis; Nasim Ahmadiyeh; Susan Lester; Sughra Raza; Parisa Lotfi; Mehra Golshan
Journal:  Ann Surg Oncol       Date:  2014-11-01       Impact factor: 5.344

2.  Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses.

Authors:  Kiran Jakate; Marina De Brot; Frank Goldberg; Derek Muradali; Frances P O'Malley; Anna Marie Mulligan
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

3.  Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.

Authors:  P J Carder; J Garvican; I Haigh; J C Liston
Journal:  Histopathology       Date:  2005-03       Impact factor: 5.087

4.  Management of papillary breast lesions diagnosed on core-needle biopsy: clinical pathologic and radiologic analysis of 276 cases with surgical follow-up.

Authors:  Monica Rizzo; Jared Linebarger; Michael C Lowe; Lin Pan; Sheryl G A Gabram; Leonel Vasquez; Michael A Cohen; Marina Mosunjac
Journal:  J Am Coll Surg       Date:  2012-01-11       Impact factor: 6.113

5.  Papillary lesions of the breast diagnosed using core needle biopsies.

Authors:  Hideaki Tokiniwa; Jun Horiguchi; Daisuke Takata; Mami Kikuchi; Nana Rokutanda; Rin Nagaoka; Ayako Sato; Hiroki Odawara; Katsunori Tozuka; Tetsunari Oyama; Izumi Takeyoshi
Journal:  Exp Ther Med       Date:  2011-08-11       Impact factor: 2.447

6.  Papillary lesions of the breast at percutaneous core-needle biopsy.

Authors:  Cecilia L Mercado; Diane Hamele-Bena; Shara M Oken; Cory I Singer; Joan Cangiarella
Journal:  Radiology       Date:  2006-01-19       Impact factor: 11.105

7.  Surgical follow-up and clinical presentation of 142 breast papillary lesions diagnosed by ultrasound-guided core-needle biopsy.

Authors:  Monica Rizzo; Mary Jo Lund; Gabriela Oprea; Matthew Schniederjan; William C Wood; Marina Mosunjac
Journal:  Ann Surg Oncol       Date:  2008-01-18       Impact factor: 5.344

8.  Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision.

Authors:  Andrew A Renshaw; Robert P Derhagopian; Dolores M Tizol-Blanco; Edwin W Gould
Journal:  Am J Clin Pathol       Date:  2004-08       Impact factor: 2.493

9.  Management of intraductal papillomas of the breast: an analysis of 129 cases and their outcome.

Authors:  Nasim Ahmadiyeh; Mariana A Stoleru; Sughra Raza; Susan C Lester; Mehra Golshan
Journal:  Ann Surg Oncol       Date:  2009-05-30       Impact factor: 5.344

10.  Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision.

Authors:  Fresia Pareja; Adriana D Corben; Sandra B Brennan; Melissa P Murray; Zenica L Bowser; Kiran Jakate; Christopher Sebastiano; Monica Morrow; Elizabeth A Morris; Edi Brogi
Journal:  Cancer       Date:  2016-06-17       Impact factor: 6.860

View more
  10 in total

1.  Intraductal Papilloma of the Breast: Prevalence of Malignancy and Natural History Under Active Surveillance.

Authors:  Jessica Limberg; Whitney Kucher; Genevieve Fasano; Syed Hoda; Aya Michaels; Jennifer L Marti
Journal:  Ann Surg Oncol       Date:  2021-04-19       Impact factor: 5.344

2.  Outcomes of classic lobular neoplasia diagnosed on breast core needle biopsy: a retrospective multi-center study.

Authors:  Iskender Sinan Genco; Bugra Tugertimur; Qing Chang; Lauren Cassell; Sabina Hajiyeva
Journal:  Virchows Arch       Date:  2019-11-27       Impact factor: 4.064

3.  Benign Breast Intraductal Papillomas Without Atypia at Core Needle Biopsies: Is Surgical Excision Necessary?

Authors:  Tanya Moseley; Bella Desai; Gary J Whitman; Emily K Robinson; Tamara Saunders; Anneliese Gonzalez; Hongying He
Journal:  Ann Surg Oncol       Date:  2020-08-28       Impact factor: 5.344

4.  Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis.

Authors:  Xiaoli Zhang; Wenqing Liu; Tao Hai; Fei Li
Journal:  Ann Surg Oncol       Date:  2021-07-30       Impact factor: 5.344

5.  Multidisciplinary Review of Intraductal Papilloma of the Breast can Identify Patients who may Omit Surgical Excision.

Authors:  Shahrzad Abbassi-Rahbar; Stephen Sack; Kelsey E Larson; Jamie L Wagner; Lyndsey J Kilgore; Christa R Balanoff; Onalisa D Winblad; Amanda L Amin
Journal:  Ann Surg Oncol       Date:  2021-08-02       Impact factor: 5.344

Review 6.  Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy.

Authors:  Edi Brogi; Melissa Krystel-Whittemore
Journal:  Mod Pathol       Date:  2020-10-26       Impact factor: 7.842

7.  Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions.

Authors:  Dogan S Polat; Jennifer G Schopp; Firouzeh Arjmandi; Jessica Porembka; Venetia Sarode; Deborah Farr; Yin Xi; Basak E Dogan
Journal:  Breast Cancer Res Treat       Date:  2020-10-03       Impact factor: 4.872

8.  Spectrum of imaging findings of papillary breast disease: A radiopathological review in a tertiary center.

Authors:  Farhana Fadzli; Kartini Rahmat; Marlina Tanty Ramli; Faizatul Izza Rozalli; Teoh Kean Hooi; Ahmad Nazran Fadzli; See Mee Hoong; Norlisah Mohd Ramli; Nur Aishah Mohd Taib
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 9.  Multiple Papillomas of the Breast: A Review of Current Evidence and Challenges.

Authors:  Rossella Rella; Giovanna Romanucci; Damiano Arciuolo; Assunta Scaldaferri; Enida Bufi; Sebastiano Croce; Andrea Caulo; Oscar Tommasini
Journal:  J Imaging       Date:  2022-07-13

10.  Breast papillary lesions diagnosed and treated using ultrasound-guided vacuum-assisted excision.

Authors:  Xiaohui Li; Hua Gao; Minling Xu; Yang Wu; Dezong Gao
Journal:  BMC Surg       Date:  2020-09-15       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.